Table 2.
Association of standardized serum free testosterone with eGFRcreat, eGFRcys, and the log-transformed ACR (mg/g), separately for men and women
| Subgroup | Outcome | Beta (95% CI), model 1 | Beta (95% CI), model 2 |
|---|---|---|---|
| Men (n = 4095) | eGFRcreat, baseline | −0.61 (−1.03; −0.19) | −0.63 (−1.05; −0.21) |
| eGFRcreat, repeated | −0.34 (−0.74; −0.05) | −0.36 (−0.75; 0.04) | |
| eGFRcys, baseline | 0.54 (0.05; 1.04) | 0.56 (0.07; 1.05) | |
| ACR, baselinea | −0.27 (−0.38; −0.16) | −0.25 (−0.35; −0.16) | |
| Women (n = 5389) | eGFRcreat, baseline | −1.03 (−1.36; −0.70) | −1.03 (−1.36; −0.71) |
| eGFRcreat, repeated | −0.77 (−1.09; −0.45) | −0.78 (−1.10; −0.46) | |
| eGFRcys, baseline | −1.05 (−1.42; −0.69) | −1.07 (−1.44; −0.70) | |
| ACR, baselinea | −0.21 (−0.99; 0.56) | −0.26 (−1.03; 0.51) |
ACR, albumin-to-creatinine ratio; CI, confidence interval; eGFRcreat, estimated glomerular filtration rate based on serum creatinine; eGFRcys, estimated glomerular filtration based on serum cystatin C; n, number.
Model 1 is adjusted for age at baseline and Rotterdam Study Cohort. Model 2 is additionally adjusted for smoking, alcohol use, and TSH.
a
Available in a subset of the population; n = 1359 for men and n = 1773 for women.